balertatug   Click here for help

GtoPdb Ligand ID: 13800

Immunopharmacology Ligand
Compound class: Antibody
Comment: Balertatug is the INN for an anti-CD70 monoclonal antibody. Peptide sequence matches this to claims in patent US8067546B2; Humanized anti-CD70 binding agents and uses thereof [1]. May align with SeaGen's clinical candidate SGN-70/SEA-CD70 that was developed for antitumour activity against CD70-positive cancers (principally myelodysplastic syndrome and acute myeloid leukemia) [2]. The antibody blocks activation of the CD70/CD27 signalling pathway that promotes stemness and proliferation of leukemic blasts. It is engineered to enhance effector functions; antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). Internal company identifier was switched to PF-08046040 when Pfizer acquired SeaGen.
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
13505 balertatug
Database Links Click here for help
GtoPdb PubChem SID 507750433
Search PubMed clinical trials balertatug
Search PubMed titles balertatug
Search PubMed titles/abstracts balertatug